Sanofi Deepens Owkin Partnership With Five-Year Deal to Build Agentic 'Biopharma Agents' for Drug Development
Sanofi will license Owkin's K Pro platform for five years and co-develop autonomous AI agents for drug R&D, extending a partnership that began in 2021 and made Owkin a unicorn.
Editor's Note ·
- Clarification:
- Four of the article's five cited sources are not on The Machine Herald editorial allowlist: owkin.com (the primary-party press release for the announcement), cdomagazine.tech and itdigest.com (industry/trade outlets), and mhealthspot.com (a niche health-tech outlet). The fifth source, Wikipedia (en.wikipedia.org), is allowlisted, and the founding and funding specifics drawn from it ($180M Sanofi investment, $255M total raised, 2016 Paris founding, K Pro details) were verified verbatim against the captured snapshot. All claims, quotes, and specifics in the article were independently confirmed against the cited source snapshots; this clarification concerns sourcing-provenance transparency only, not any factual error.
Overview
French-American AI and biotech company Owkin will build a suite of autonomous “biopharma agents” for Sanofi under a multi-year collaboration anchored by a five-year license for Owkin’s K Pro platform, the company announced in early June. According to Owkin, the agents will “work like intelligent assistants, autonomously performing complex tasks in drug research and development,” deployed through K Pro to complement and reinforce Sanofi’s existing agentic AI capabilities.
The deal extends a relationship that began in 2021 and continues a broader pattern across the pharmaceutical industry, in which large drugmakers are licensing specialized AI platforms rather than building every capability in house.
What We Know
Under the agreement, Owkin will lead the end-to-end development of biopharma agents purpose-built for Sanofi, according to Owkin. K Pro, the platform the agents run on, “combines multimodal patient data with specialized biological, agentic AI systems to support each stage of the pharmaceutical value chain, from early discovery through clinical development,” the company says. As reported by mHealthSpot, the agents analyze multimodal patient data including genetic information, medical imaging, and clinical records.
The collaboration runs for five years through a license for K Pro, according to CDO Magazine. The companies did not disclose a financial value for the new agreement.
Thomas Clozel, CEO and co-founder of Owkin, framed the deal as a move from external tooling toward systems embedded inside a partner’s own operations. “Building on our collaboration with Sanofi, this marks a shift toward truly embedded AI. Owkin believes that, with K Pro, Sanofi can further harness agentic systems within their own workflows, unlocking the full value of their data to accelerate better decisions across drug development,” he said, according to Owkin.
Emmanuel Frenehard, Chief Digital Officer at Sanofi, said the company is “continually investing in frontier AI solutions with the potential to accelerate and improve decision-making throughout the drug development lifecycle.” He added: “By implementing purpose-built agentic systems into our workflows, we aim to empower our teams to operate with greater speed, depth, and confidence as we continue to work to deliver transformative outcomes for patients,” according to Owkin.
Background
The two companies are not new partners. Owkin and Sanofi began collaborating in 2021 under a €90 million strategic partnership initially focused on target identification in oncology and patient subgrouping, later expanded to drug positioning for Sanofi’s immunology pipeline, according to Owkin. CDO Magazine reports the original collaboration centered on oncology target identification and patient stratification before broadening to immunology.
Sanofi’s involvement with Owkin runs deeper than a research contract. Owkin was founded in Paris in 2016 by Thomas Clozel and Gilles Wainrib, a professor of artificial intelligence, according to Wikipedia. The company became a unicorn — a startup valued at more than $1 billion — in November 2021 through a $180 million investment from Sanofi, and has raised over $255 million in total, per Wikipedia. In other words, the same partner now licensing Owkin’s agentic platform also helped mint its billion-dollar valuation.
K Pro itself is relatively new. It was first released in May 2025 and draws on 26.5 million scientific articles, 19 biomedical databases, and multiomic data from Owkin’s MOSAIC, according to Wikipedia.
Analysis
The Sanofi agreement is not an isolated bet. In May 2026, Owkin signed a separate three-year K Pro license agreement with AstraZeneca, under which Owkin will develop AI agents that run on K Pro inside AstraZeneca’s IT infrastructure to help decision-making teams access insights for competitive-intelligence questions while reducing manual analysis, according to IT Digest. Clozel put the strategy bluntly in that announcement: “At Owkin, we believe the future of the pharmaceutical industry is agentic,” he said, per IT Digest.
Two deals with two of the world’s largest drugmakers in roughly a month point to a licensing model: rather than selling a static analytics product, Owkin is positioning K Pro as the substrate on which it builds bespoke autonomous agents tailored to each customer’s data and workflows. For pharmaceutical companies, the appeal is integrating AI into existing decision-making pipelines without assembling the underlying multimodal data and modeling stack themselves.
What We Don’t Know
Neither company disclosed a financial value for the new Sanofi agreement, the specific number of agents to be built, or concrete performance targets. It also remains to be seen how the new agents will measurably affect Sanofi’s drug-development timelines — the kind of outcome that, by the nature of multi-year pharmaceutical R&D, will take years to assess.